This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Epidermal Growth Factor Receptor-Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody Panitumumab
- Production of Multimeric Prostate-Specific Membrane Antigen Small-Molecule Radiotracers Using a Solid-Phase 99mTc Preloading Strategy
- Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis
- Biodistribution and Therapeutic Efficacy of 125/131I-, 186Re-, 88/90Y-, or 177Lu-Labeled Monoclonal Antibody MN-14 to Carcinoembryonic Antigen in Mice with Small Peritoneal Metastases of Colorectal Origin
- Optimization of Radioimmunotherapy of Renal Cell Carcinoma: Labeling of Monoclonal Antibody cG250 with 131I, 90Y, 177Lu, or 186Re
- Dosimetric Analysis of Radioimmunotherapy with 186Re-Labeled Bivatuzumab in Patients with Head and Neck Cancer
- Final Results of a Phase I Radioimmunotherapy Trial Using 186Re-Epratuzumab for the Treatment of Patients with Non-Hodgkin's Lymphoma
- Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma
- 89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies
- Optimal Quality 131I-Monoclonal Antibodies on High-Dose Labeling in a Large Reaction Volume and Temporarily Coating the Antibody with IODO-GEN
- Two-Step Targeting of Xenografted Colon Carcinoma Using a Bispecific Antibody and 188Re-Labeled Bivalent Hapten: Biodistribution and Dosimetry Studies
- Phase I Therapy Study of 186Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck